Document Detail


Evaluation of a venous-return assist device to treat severe post-thrombotic syndrome (VENOPTS). A randomized controlled trial.
MedLine Citation:
PMID:  18327413     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Severe post-thrombotic syndrome (PTS) is responsible for considerable disability, reduced quality of life and increased health care costs. Current therapies are limited and often ineffective. We performed a two-centre, randomized, cross-over controlled trial to evaluate Venowave, a novel lower-limb venous-return assist device, for the treatment of severe PTS. Eligible subjects were allocated to receive, in randomized order, Venowave for eight weeks and a control device for eight weeks. The eight-week treatment periods were separated by a four-week period when no device was used (i.e. wash-out period). The primary outcome measure was a 'clinical success' defined as: i) reported benefit from the device; and ii) moderate or greater improvement in symptoms of PTS; and iii) willingness to continue using the device. Secondary outcome measures included quality of life (QOL) as measured by VEINES-QOL questionnaire (higher scores indicate better QOL), and PTS severity as measured by the Villalta PTS scale (higher scores indicate more severe PTS). The study was registered with Clinical Trials. gov (NCT00182208). Thirty-two patients were enrolled. Of these, 26 (80%) were also using graduated compression stockings. Twenty-six participants completed both trial periods. Clinical success occurred in 10 (31%) participants receiving Venowave and four (13%) participants receiving the control device, with two (6%) participants reporting a clinical success with both devices (P = 0.11). Mean VEINES-QOL score at the end of study period was significantly greater (P = 0.004) for Venowave (52.5; SD 5.8) compared to control (50.2; SD 6.2). Mean Villalta scale score at the end of study period was significantly decreased (P = 0.004) for Venowave (12.2; SD 6.3) compared to control (15.0; SD 6.1). In conclusion, Venowave appears to be a very promising new therapy for patients with severe PTS, which may be used alone or in combination with graduated compression stockings.
Authors:
Martin J O'Donnell; Simon McRae; Susan R Kahn; Jim A Julian; Clive Kearon; Betsy Mackinnon; Debbie Magier; Carla Strulovich; Theresa Lyons; Sandra Robinson; Jack Hirsh; Jeffrey S Ginsberg
Related Documents :
19693523 - Hemoglobin levels predict quality of life in women with heavy menstrual bleeding.
18230833 - Reduced quality of life in patients with head-and-neck paragangliomas.
19860883 - Randomised controlled trial of local corticosteroid injections for de quervain's tenosy...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  99     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2008 Mar 
Date Detail:
Created Date:  2008-03-10     Completed Date:  2008-05-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  623-9     Citation Subset:  IM    
Affiliation:
Henderson Research Centre, McMaster University, Hamilton, Ontario, Canada. odonnm@mcmaster.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Canada
Cross-Over Studies
Double-Blind Method
Equipment Design
Female
Humans
Intermittent Pneumatic Compression Devices* / adverse effects
Male
Middle Aged
Patient Compliance
Patient Satisfaction
Postthrombotic Syndrome / therapy*
Quality of Life
Questionnaires
Severity of Illness Index
Stockings, Compression*
Time Factors
Treatment Outcome
Comments/Corrections
Comment In:
Thromb Haemost. 2008 Mar;99(3):463-4   [PMID:  18327391 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic int...
Next Document:  Epidemiology of hepatitis C virus infection in Pakistan.